Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous TIM-4 chimeric engulfment receptor T cells CER-1236

A preparation of autologous T cells genetically engineered to express a chimeric engulfment receptor (CER) that contains the phosphatidylserine (PS) receptor T-cell immunoglobulin and mucin domain-containing protein 4 (TIM-4) extracellular signaling domain linked to the transmembrane domain of the co-stimulatory signaling protein CD28 and the zeta chain of the TCR/CD3 complex (CD3-zeta) fused to the Toll/interleukin-1 receptor (TIR) domain from Toll-like receptor 2 (TLR-2; TLR2; Toll/Interleukin 1 Receptor-Like 4) (TLR2-TIR) as an additional innate signaling domain to enhance antigen-presenting cell (APC)-function, with potential phagocytic, immunomodulating and antineoplastic activities. Upon administration, autologous TIM-4 CER T cells CER-1236 target and bind to the phospholipid and TIM-4 ligand (TIM-4-L) phosphatidylserine expressed on tumor cells. This binding induces cytolytic and phagocyte-like engulfment activity of the CER T cells, thereby killing TIM-4-L expressing tumor cells. Activation of the T-cell signaling domains activate and enhance the cytotoxic T-lymphocyte response against the tumor cells, thereby further killing tumor cells. In addition, the tumor-associated antigens (TAAs) that are leaked from the tumor cells are taken up by CER-1236 and are processed and presented to the immune system through an APC-like presentation, thereby inducing secondary immune responses and activating bystander T cells. Aberrant TIM-4-L expression is observed on malignant cells of multiple lineages, but its expression is minimal on normal, healthy cells.
Synonym:autologous TIM-4 CER-CD28-CD3zeta-TLR2-TIR-expressing T cells CER-1236
autologous TIM4 CER T cells CER-1236
Code name:CER 1236
CER-1236
CER1236
Search NCI's Drug Dictionary